

The Hospital for Sick Children

Technology Assessment at Sick Kids (TASK)

APPENDICES

THIOPURINE DOSING USING THIOPURINE METHYLTRANSFERASE STATUS: A SYSTEMATIC REVIEW OF CLINICAL GUIDANCE

Authors:

Heather Burnett, MSc
Research Project Coordinator, Child Health Evaluative Sciences,
The Hospital for Sick Children, Toronto

Reo Tanoshima, MD
Clinical Fellow, Division of Clinical Pharmacology and Toxicology,
The Hospital for Sick Children, Toronto

Weerawadee Chandranipapongse, MD
Clinical Fellow, Division of Clinical Pharmacology and Toxicology,
The Hospital for Sick Children, Toronto

Parvaz Madadi, PhD
Research Fellow, Clinical Pharmacology and Toxicology,
The Hospital for Sick Children, Toronto

Shinya Ito, MD, FRCP(C)
Division Head, Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto
Senior Scientist, Physiology & Experimental Medicine, The Hospital for Sick Children, Toronto
Professor, Medicine, Pharmacology & Pharmacy, Department of Paediatrics,
University of Toronto

Wendy J. Ungar, MSc, PhD
Senior Scientist, Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto
Associate Professor, Health Policy, Management & Evaluation, University of Toronto

Report No. 2013-02

Date: November 27, 2013

Available at: <http://lab.research.sickkids.ca/task/reports-theses/>

ACKNOWLEDGEMENTS

Funding for this research was provided by a program grant from the Ontario Ministry of Health and Long-Term Care Drug Innovation Fund.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

For more information contact:

Wendy J. Ungar, M.Sc., Ph.D.
Senior Scientist, Child Health Evaluative Sciences
The Hospital for Sick Children Peter Gilgan Centre for Research and Learning
11th floor, 686 Bay Street
Toronto, ON, Canada M5G 0A4

tel: (416) 813-7654, extension 303487

fax: (416) 813-5979

e-mail: wendy.ungar@sickkids.ca

<http://www.sickkids.ca/AboutSickKids/Directory/People/U/Wendy-Ungar.html>

APPENDIX 1: LITERATURE SEARCH STRATEGIES

CINAHL

1. (PT Practice Guidelines) OR (TI guideline*) OR (TI guidance*) OR (TI (position paper or position stand)) OR (TI statement*) OR (TI recommendation*) OR (TI consensus) OR (TI practice parameter*) OR (TI standards)
2. KW(TPMT OR "thiopurine methyltransferase" OR "thiopurine methyl transferase" OR "thiopurine" OR "azathioprine" OR "mercaptapurine" OR "6-mercaptapurine" OR "thioguanine" OR "6-thioguanine")
3. MH (Azathioprine) OR (MH 6-Mercaptopurine)
4. 2 OR 3
5. 1 AND 4

MEDLINE

1. exp Practice Guideline/ or exp Guideline/ or exp Clinical Protocols/ or exp Critical Pathways/ or exp Decision Support Systems, Clinical/
2. (guideline or guidance or "clinical protocol" or "care pathway" or "pathway of care" or "care map*" or "decision support" or "clinical information system" or "medical pathway" or "clinical annotation" or "recommendation" or "clinical recommendation*" or "clinical consensus" or "consensus statement")
3. 1 or 2
4. (TPMT* or "thiopurine methyltransferase*" or "thiopurine s-methyltransferase*" or "thiopurine methyl-transferase*" or "thiopurine s-methyl-transferase*" or "thiopurinemethyltransferase*")
5. exp 6-mercaptapurine/ or exp azathioprine/ or exp thioguanine/
6. 4 or 5
7. 3 and 6

EMBASE

1. exp Practice Guideline/ or exp clinical protocol/ or exp clinical pathway/ or exp decision support system/ or exp consensus/
2. (guideline or guidance or "clinical protocol" or "care pathway" or "pathway of care" or "care map*" or "decision support" or "clinical information system" or "medical pathway" or "clinical annotation" or "recommendation" or "clinical recommendation*" or "clinical consensus" or "consensus statement")
3. 1 or 2
4. (TPMT* or "thiopurine methyltransferase*" or "thiopurine s-methyltransferase*" or "thiopurine methyl-transferase*" or "thiopurine s-methyl-transferase*" or "thiopurinemethyltransferase*")
5. exp thiopurine methyltransferase/
6. 4 or 5
7. 3 and 6

APPENDIX 2: GREY LITERATURE SOURCES

Guideline sources	Website
General guideline sources	
Guidelines International Network	http://www.g-i-n.net/
National Guideline Clearinghouse	http://guideline.gov/
NICE guidance (UK)	http://guidance.nice.org.uk/
Nice pathways (UK)	http://pathways.nice.org.uk/
Scottish Intercollegiate Guidelines Network (SIGN)	http://www.sign.ac.uk/
New Zealand Guidelines Group	http://www.nzgg.org.nz/
Guidelines Advisory Committee (GAC) - Ontario	http://www.gacguidelines.ca/
SUM2 - University of Kansas School of Medicine & Medical Center	http://sumsearch.org/
Canadian Medical Association Infobase	http://www.cma.ca/index.php/ci_id/54316/la_id/1.htm
BC guidelines	http://www.bcguidelines.ca/
eGuidelines (UK) (requires login)	http://www.eguidelines.co.uk/
Medical Journal of Australia Guidelines	https://www.mja.com.au/journal/guidelines
Pharmacogenomics-related sources	
The Pharmacogenomics Knowledgebase	http://www.pharmgkb.org
Disease specific (cancer)	
Children's Oncology Group	http://www.childrensoncologygroup.org/
SAGE Inventory of Cancer Guidelines	http://cancerguidelines.ca/Guidelines/inventory/search.php
Disease specific (gastroenterology)	
The American Gastroenterological Association	http://www.gastro.org/practice/medical-position-statements
Canadian Association of Gastroenterology	http://www.cag-acg.org/guidelines
World Gastroenterology Organization	http://www.worldgastroenterology.org/global-guidelines.html
British Society for Gastroenterology	http://www.bsg.org.uk/clinical/general/guidelines.html
American College of Gastroenterology	http://gi.org/clinical-guidelines/clinical-guidelines-sortable-list/

Pediatric specific	
Cincinnati Children's Hospital: Evidence-based guidelines	http://www.cincinnatichildrens.org/service/i/anderson-center/evidence-based-care/default/
Great Ormond Street Hospital Trust (NHS Foundation Trust) (UK)	http://www.gosh.nhs.uk/health-professionals/clinical-guidelines/
The Royal Children's Hospital (Australia)	http://www.rch.org.au/clinicalguide/cpg.cfm
Auckland District Health Board (New Zealand) – Newborn guidelines	http://www.adhb.govt.nz/newborn/Guidelines.htm
Royal College of Paediatrics and Child Health (UK)	http://www.rcpch.ac.uk/supported-guidelines

APPENDIX 3: AGREE-II INSTRUMENT

Domain	Item	AGREE II Rating						
		1 <i>Strongly Disagree</i>	2	3	4	5	6	7 <i>Strongly Agree</i>
Scope and purpose	1. The overall objective(s) of the guideline is (are) specifically described.							
	2. The health question(s) covered by the guideline is (are) specifically described.							
	3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described.							
Stakeholder involvement	4. The guideline development group includes individuals from all the relevant professional groups.							
	5. The views and preferences of the target population (patients, public, etc.) have been sought.							
	6. The target users of the guideline are clearly defined.							
Rigor of development (shaded items focused on TPMT recommendations)	7. Systematic methods were used to search for evidence.							
	8. The criteria for selecting the evidence are clearly described.							
	9. The strengths and limitations of the body of evidence are clearly described.							
	10. The methods for formulating the recommendations are clearly described.							
	11. The health benefits, side effects and risks have been considered in formulating the recommendations.							
	12. There is an explicit link between the recommendations and the supporting evidence.							
	13. The guideline has been externally reviewed by experts prior to its publication.							
	14. A procedure for updating the guideline is provided.							
Clarity of presentation	15. The recommendations are specific and unambiguous.							
	16. The different options for management of the condition or health issue are clearly presented.							
	17. Key recommendations are easily identifiable.							
Applicability	18. The guideline describes facilitators and barriers to its application.							
	19. The guideline provides advice and/or tools on how the recommendations can be put into practice.							
	20. The potential resource implications of applying the recommendations have been considered.							
	21. The guideline presents monitoring and/ or auditing criteria.							
Editorial independence	22. The views of the funding body have not influenced the content of the guideline.							
	23. Competing interests of guideline development group members have been recorded and addressed.							
Overall Guideline Assessment	1. Rate the overall quality of this guideline.	1 <i>Lowest possible quality</i>	2	3	4	5	6	7 <i>Highest possible quality</i>
	2. I would recommend this guideline for use.	Yes	Yes, with modifications				No	